Future Directions in the Development of New Antitubercular Drugs. Where Do We Go from Here?

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 1997 Jun 1

PMID 9205846

Authors

W W Yew

C H Chau

Affiliations

Soon will be listed here.

Abstract

The global resurgence of tuberculosis and rampant drug resistance have rekindled the need for and interest in the development of new antitubercular drugs. Delineation of the possible drug targets furnished by the various mycobacterial cell components might result in rational approaches to the development of such agents. In the future, molecular genetics might help both in the bioengineering and rapid screening of the activity of new compound. Collaboration is anticipated between the pharmaceutical industry and academic institutions in these areas.

References

Dickinson J, Mitchison D . In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle. 1987; 68(2):113-8. DOI: 10.1016/0041-3879(87)90026-2. View

Kayok T, Reddy M, Chinnaswamy J, Danziger L, GANGADHARAM P . Activity of aminosidine (paromomycin) for Mycobacterium tuberculosis and Mycobacterium avium. J Antimicrob Chemother. 1994; 33(2):323-7. DOI: 10.1093/jac/33.2.323. View

Zhang Y, Lathigra R, Garbe T, Catty D, Young D . Genetic analysis of superoxide dismutase, the 23 kilodalton antigen of Mycobacterium tuberculosis. Mol Microbiol. 1991; 5(2):381-91. DOI: 10.1111/j.1365-2958.1991.tb02120.x. View

MEHTA R, Keyhani A, McQueen T, Rosenbaum B, Rolston K, Tarrand J . In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis. Antimicrob Agents Chemother. 1993; 37(12):2584-7. PMC: 192745. DOI: 10.1128/AAC.37.12.2584. View

Dolin P, Raviglione M, Kochi A . Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ. 1994; 72(2):213-20. PMC: 2486541. View

Natal S, Yongchaiyud P, Olliaro P . Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. Tuber Lung Dis. 1994; 75(5):341-7. DOI: 10.1016/0962-8479(94)90079-5. View

Sirgel F, Botha F, Parkin D, van de Wal B, Donald P, CLARK P . The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother. 1993; 32(6):867-75. DOI: 10.1093/jac/32.6.867. View

Kennedy N, Fox R, Kisyombe G, Saruni A, Uiso L, Ramsay A . Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis. 1993; 148(6 Pt 1):1547-51. DOI: 10.1164/ajrccm/148.6_Pt_1.1547. View

Yew W, Lee J, Wong P, Kwan S . Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. Int J Clin Pharmacol Res. 1992; 12(4):173-8. View

10.

Chaisson R, Benson C, Dube M, Heifets L, Korvick J, Elkin S . Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med. 1994; 121(12):905-11. DOI: 10.7326/0003-4819-121-12-199412150-00001. View

11.

Schwander S, Rusch-Gerdes S, Mateega A, Lutalo T, Tugume S, Kityo C . A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis. 1995; 76(3):210-8. DOI: 10.1016/s0962-8479(05)80007-3. View

12.

. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council. Tuber Lung Dis. 1992; 73(1):59-67. View

13.

Rastogi N, Goh K, David H . Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis. Antimicrob Agents Chemother. 1990; 34(5):759-64. PMC: 171687. DOI: 10.1128/AAC.34.5.759. View

14.

Zhang Y, Heym B, Allen B, Young D, Cole S . The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992; 358(6387):591-3. DOI: 10.1038/358591a0. View

15.

Jagannath C, Reddy M, Kailasam S, OSullivan J, GANGADHARAM P . Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med. 1995; 151(4):1083-6. DOI: 10.1164/ajrccm/151.4.1083. View

16.

Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston M . Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993; 341(8846):647-50. DOI: 10.1016/0140-6736(93)90417-f. View

17.

Chan S, Yew W, Ma W, Girling D, Aber V, Felmingham D . The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis. 1992; 73(1):33-8. DOI: 10.1016/0962-8479(92)90077-W. View

18.

Bodmer T, Zurcher G, Imboden P, Telenti A . Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 1995; 35(2):345-8. DOI: 10.1093/jac/35.2.345. View

19.

Young L, Berlin O, Inderlied C . Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med. 1987; 82(4A):23-6. View

20.

Rastogi N, Frehel C, RYTER A, Ohayon H, Lesourd M, David H . Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents?. Antimicrob Agents Chemother. 1981; 20(5):666-77. PMC: 181770. DOI: 10.1128/AAC.20.5.666. View